Human randomized controlled trial

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

A multicentre randomized phase 2 trial in 131 patients with HER2-negative stage II or III breast cancer.

Nat Commun, 2020. de Groot S, et al.

Funding and competing interests (as published with the paper): V.D.L. has equity interest in L-Nutra. H.P. has shares in a company that invested in L-Nutra. The remaining authors declare no competing interests.

Read the full study

Opens the journal or PubMed page in a new tab. Some journals require a subscription.

Study type
Human clinical trial (randomized, phase 2, n=131)
Journal
Nat Commun
Published
2020
Authors
de Groot S, et al.
DOI
10.1038/s41467-020-16138-3
PubMed ID
32576828

Summary

One hundred and thirty-one patients with HER2-negative stage II or III breast cancer, without diabetes and with a BMI over 18, were randomly assigned to receive either a Fasting Mimicking Diet (FMD) or their regular diet for three days before and during neoadjuvant chemotherapy. Dexamethasone was omitted in the diet group. The authors assessed toxicity, radiological and pathological response, and chemotherapy-induced DNA damage in T-lymphocytes.

The authors reported no difference in toxicity between the two groups, despite dexamethasone being omitted in the diet group. They reported that a radiologically complete or partial response occurred more often in patients using the diet. They reported that in a per-protocol analysis a Miller and Payne 4 or 5 pathological response, indicating 90% to 100% tumour cell loss, was more likely in patients using the diet. They also reported that the diet reduced chemotherapy-induced DNA damage in T-lymphocytes, and described their findings as encouragement for further exploration.

The pathological response finding comes from a per-protocol analysis, which compares the patients who followed the diet rather than everyone as randomized, and that is a weaker comparison than the trial's randomization supports. Participants were breast cancer patients receiving neoadjuvant chemotherapy, not a general wellness population, and the diet was given only around chemotherapy rounds. The study does not evaluate Prolon directly, and the authors themselves frame the results as grounds for further exploration rather than as a settled finding.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.